CD37-Binding Molecules and Immunoconjugates Thereof
AssigneeImmunoGen, Inc.
InventorsJutta DECKERT, Peter Park, Daniel Tavares, Lingyun Rui
Life of this patent
Estimating the term…
Abstract
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
Claims52
An antibody or antigen binding fragment thereof that specifically binds to CD37, wherein said antibody or fragment thereof is capable of inducing complement dependent cytotoxicity (CDC).
(canceled)
7-17. (canceled)
A human or humanized antibody or antigen binding fragment thereof that specifically binds to CD37, wherein said antibody or fragment thereof is capable of inducing apoptosis of a cell expressing CD37 in vitro in the absence of cross-linking agents.
25-28. (canceled)
33-38. (canceled)
(canceled)
(canceled)
(canceled)
48-50. (canceled)
(canceled)
(canceled)
(canceled)
59-66. (canceled)
Dependencies are inferred from the claim text.